Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 1/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5951002 | 0.78 | CHRNA7 (0.37) | — | |
| SCHEMBL23768366 | 0.76 | TRPM8 (0.42) | HCAR3TRPM8TDP1GABRA1GABRG2 | |
| SCHEMBL17723382 | 0.75 | ENPP2 (0.48) | — | |
| SCHEMBL17723355 | 0.75 | MAPKAPK2 (0.40) | — | |
| SCHEMBL12411080 | 0.74 | GAA (0.54) | HCAR3TRPM8TDP1 | |
| SCHEMBL10212536 | 0.74 | HCAR3 (0.38) | HCAR3TRPM8TDP1GABRA1GABRG2 | |
| SCHEMBL17723367 | 0.74 | PDPK1 (0.38) | — | |
| SCHEMBL19105514 | 0.74 | CHRNA7 (0.31) | — | |
| SCHEMBL17723306 | 0.73 | JAK2 (0.33) | — | |
| SCHEMBL12411082 | 0.72 | LMNA (0.42) | HCAR3TRPM8PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230192704-A1 | MONOCARBOXYLIC ACID TRANSPORTER 4 (MCT4) MODULATORS AND USES THEREOF | TEON THERAPEUTICS INC (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230141913-A2 | PHENOXY(HETERO)ARYL ETHERS OF ANTIPROLIFERACTIVE ACTIVITY | Xeniopro GmbH (DE) | 2023-05-11 | — | — | US | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
| US-20170240586-A1 | Benzoic Acid Derivatives of Bile Acid as FXR/TGR5 Agonists and Methods of Use Thereof | ENANTA PHARMACEUTICALS, INC. | 2017-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | CRBN, CDR2, MDM2 | HCAR3 3811/4885TRPM8 4604/4885TDP1 1939/4885 |
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | HCAR3 763/4885TRPM8 4476/4885TDP1 236/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HCAR3 763/4885TRPM8 4476/4885TDP1 236/4885 |
| US-20230141913-A2 | PHENOXY(HETERO)ARYL ETHERS OF ANTIPROLIFERACTIVE ACTIVITY | AHR, MUSK, TYR | HCAR3 638/4885TRPM8 3502/4885TDP1 1357/4885 |
| US-20230192704-A1 | MONOCARBOXYLIC ACID TRANSPORTER 4 (MCT4) MODULATORS AND USES THEREOF | SLC16A3, SLC16A1, SLC16A8 | HCAR3 157/4885TRPM8 690/4885TDP1 3965/4885 |
| US-20170240586-A1 | Benzoic Acid Derivatives of Bile Acid as FXR/TGR5 Agonists and Methods of Use Thereof | GPBAR1, NR1H4, SLC10A1 | HCAR3 58/4885TRPM8 1186/4885TDP1 2347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.